Journal article icon

Journal article

Profound structural conservation of chemically cross-linked HIV-1 envelope glycoprotein experimental vaccine antigens

Abstract:
Chemical cross-linking is used to stabilize protein structures with additional benefits of pathogen and toxin inactivation for vaccine use, but its use has been restricted by the potential for local or global structural distortion. This is of particular importance when the protein in question requires a high degree of structural conservation for inducing a biological outcome such as the elicitation of antibodies to conformationally sensitive epitopes. The HIV-1 envelope glycoprotein (Env) trimer is metastable and shifts between different conformational states, complicating its use as a vaccine antigen. Here we have used the hetero-bifunctional zero-length reagent 1-Ethyl-3-(3-Dimethylaminopropyl)-Carbodiimide (EDC) to cross-link two soluble Env trimers, selected well-folded trimer species using antibody affinity, and transferred this process to good manufacturing practice (GMP) for experimental medicine use. Cross-linking enhanced trimer stability to biophysical and enzyme attack. Cryo-EM analysis revealed that cross-linking retained the overall structure with root-mean-square deviations (RMSDs) between unmodified and cross-linked Env trimers of 0.4-0.5 Å. Despite this negligible distortion of global trimer structure, we identified individual inter-subunit, intra-subunit, and intra-protomer cross-links. Antigenicity and immunogenicity of the trimers were selectively modified by cross-linking, with cross-linked ConS retaining bnAb binding more consistently than ConM. Thus, the EDC cross-linking process improves trimer stability whilst maintaining protein folding, and is readily transferred to GMP, consistent with the more general use of this approach in protein-based vaccine design
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Publisher copy:
10.1038/s41541-023-00696-w
Publication website:
http://edoc.mdc-berlin.de/23640/1/23640oa.pdf

Authors

More by this author
Role:
Author
ORCID:
0000-0002-2913-9108
More by this author
Institution:
University of Oxford
Role:
Author
ORCID:
0000-0002-1777-7479
More by this author
Role:
Author
ORCID:
0000-0002-9095-5657
More by this author
Institution:
University of Oxford
Role:
Author
ORCID:
0000-0001-5717-4093
More by this author
Institution:
University of Oxford
Role:
Author
ORCID:
0000-0001-8756-1836


More from this funder
Funder identifier:
10.13039/100000865
Grant:
OPP1115782
More from this funder
Funder identifier:
10.13039/100010661
Grant:
681137


Publisher:
Nature Research
Journal:
npj Vaccines More from this journal
Volume:
8
Issue:
1
Pages:
101-101
Article number:
101
Publication date:
2023-07-13
DOI:
EISSN:
2059-0105
ISSN:
2059-0105


Language:
English
Keywords:
Pubs id:
1493357
Local pid:
pubs:1493357
Source identifiers:
W4384203234
Deposit date:
2026-05-11
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP